PRTC News and Press, PureTech Health plc From 08/30/23

2023-08-30 02:01:30 ET More on PureTech PureTech bags $11.4M from U.S. Department of Defense contract Vedanta Biosciences raises $106.5M to fund drug development programs Royalty Pharma, PureTech in pact for royalties in Karuna’s lead asset PureTech He...

2023-08-01 07:38:27 ET Clinical-stage biotherapeutics company PureTech Health ( NASDAQ: PRTC ) has been awarded up to $11.4M from the U.S. Department of Defense to advance its therapeutic candidate, LYT-300 (oral allopregnanolone), for the treatment of Fragile X-associated ...

Planning underway for Phase 2 trial of LYT-300 in Fragile X-associated Tremor/Ataxia Syndrome LYT-300 is also being evaluated in a Phase 2a trial for anxiety disorders, and a Phase 2a in patients with postpartum depression is planned to initiate in second half of 2023 LYT-300, LYT...

Results from a validated clinical model of anxiety in healthy volunteers anticipated by the end of 2023 Phase 2a clinical trial of LYT-300 in patients with postpartum depression planned to initiate in second half of 2023 LYT-300 is derived from PureTech’s Glyph TM ...

The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Tuesday, June 13, 2023. All of the resolutions proposed at the Annual General Meeting were duly passed by the shar...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Eric Elenko, Ph.D., Chief Innovation Officer, and Julie Krop, M.D., Chief Medical Off...

VE303 receives Fast Track designation for prevention of recurrent C. difficile infection ahead of global pivotal Phase 3 study Exploratory analyses from the VE303 Phase 2 CONSORTIUM study identify statistically significant relationships between VE303 bacterial species and multiple par...

Attention improved in more than 80 percent of adults with ADHD, and over one-third of participants no longer exhibited an attention deficit following treatment Improvements in attention were nearly seven times larger than those seen in the pivotal trial that supported EndeavorRx’s ...

2023-04-28 07:45:05 ET PureTech press release ( NASDAQ: PRTC ): FY GAAP EPS of -$0.18. Revenue of $15.62M (-10.2% Y/Y). For further details see: PureTech GAAP EPS of -$0.18, revenue of $15.62M

Strong capital base with PureTech level cash, cash equivalents and short-term investments of $339.5 million 1 and consolidated cash, cash equivalents and short-term investments of $350.1 million, 2 as of December 31, 2022. Rapid advancement of PureTech’s Wholly Owned Pi...